Contrast-induced Nephropathy: Incidence and Reversibility in Patients Undergoing High-risk Percutaneous Coronary Intervention

Author:

Sambyal Bharat Singh1,Kansal Vishal2,Nayak Akshay Kumar1,Chauhan Prabhat1,Jeldi Kavya1

Affiliation:

1. Department of Internal Medicine, Inhs Asvini, New Delhi, India

2. Department of Physiology, AH R & R, New Delhi, India

Abstract

Abstract Introduction: There is a paucity of data regarding contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary intervention (PCI) from this part of the world. The present study was thus planned to find the incidence and reversibility of CIN in patients undergoing high-risk PCI. Materials and Methods: A hospital-based observational study was conducted at the department of cardiology in a tertiary care hospital. The study included 50 consecutive cases undergoing high-risk PCI at the cardiac catheterization laboratory. CIN is characterized as either a relative increase in serum creatinine (S. Cr) of 25% or more or an absolute increase of 0.5 mg/dL or more, occurring within 48 h of exposure to contrast media. This is under the assumption that there are no other factors contributing to the increase in S. Cr. Results: The incidence of CIN in cases undergoing high-risk percutaneous interventions was 18% in the present study. On regression analysis, age above 70 years, hypertension and diabetes were identified as significant predictors of the development of CIN in patients undergoing cardiac procedures in the cardiac catheterization laboratory (P < 0.01). All the cases of CIN had a self-limiting course, and none of the cases required renal replacement therapy. Conclusion: CIN affects one out of every five to six cases undergoing high-risk PCI; however, almost all cases are reversible. Patients with preexisting comorbidities such as diabetes and hypertension have a significantly increased risk of development of CIN.

Publisher

Medknow

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3